TQ-B3456 / Sino Biopharm - LARVOL DELTA

A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=50 ➔ 1 | Trial completion date: May 2020 ➔ Feb 2022 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2019 ➔ Feb 2022; The enrolment task cannot be gotten within the planned time.It mainly includes patients with non-small cell lung cancer failed in standard treatment,with a short survival period.It is hard to obtain observational endpoints for bone-related events.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd

New P1 trial